Table 2 Univariate analyses of potential predictors of survival in 271 HCC patients.

Age (y)

0.945

 <60

177

16.3 ± 1.12

1

 ≥60

94

16.9 ± 1.98

0.99(0.75–1.31)

0.945

Gender

0.853

  Female

44

16.9 ± 2.33

1

  Male

227

16.1 ± 1.12

1.03(0.72–1.48)

0.853

HBsAg

0.059

  Negative

30

20.8 ± 2.89

1

  Positive

241

16.0 ± 1.06

1.53(0.98–2.39)

0.061

ALT (IU/ml)

0.016

 <75

231

16.7 ± 1.08

1

 ≥75

40

14.6 ± 2.58

1.54(1.08–2.20)

0.017

AST (IU/mL)

0.017

 <75

233

16.9 ± 1.05

1

 ≥75

38

13.2 ± 1.89

1.56(1.08–2.26)

0.018

 AFP

0.030

  <20

98

19.7 ± 2.00

1

  ≥20

173

15.2 ± 1.10

1.37(1.03–1.81)

0.031

Child-Pugh classification

0.001

 A

228

17.4 ± 1.28

1

 B

43

14.4 ± 2.47

1.80(1.26–2.56)

0.001

BCLC stage

0.002

 B

149

20.8 ± 1.19

1

 C

122

13.1 ± 1.28

1.51(1.15–1.98)

0.003

Tumour Size

0.514

 <5

94

16.9 ± 1.55

1

 ≥5

177

16.1 ± 1.54

0.91(0.69–1.21)

0.515

Intrahepatic tumour number

<0.001

 Solitary

128

23.4 ± 1.96

1

 Multiple

143

12.4 ± 1.52

2.32(1.76–3.05)

<0.001

 Prior treatments

0.210

  None

29

15.2 ± 4.55

1

  TACE only

141

16.1 ± 0.92

0.85(0.55–1.32)

0.469

  Operation ± TACE

101

17.8 ± 2.15

0.72(0.46–1.14)

0.158

EBRT dose (Gy)

0.028

  ≤50

137

15.0 ± 0.80

1

  >50

134

18.7 ± 1.91

0.74(0.57–0.97)

0.029

 Radiation technique

0.025

  3D-CRT

135

15.2 ± 1.28

1

  HT

136

18.4 ± ‘1.75

1.36(1.04–1.78)

0.025

LN metastases

0.106

  Absence

207

17.0 ± 1.23

1

  Presence

64

15.2 ± 1.30

1.29(0.95–1.77)

0.108

 Distance metastases

0.276

  Absence

253

16.9 ± 0.98

1

  Presence

18

11.0 ± 1.78

1.37(0.78–2.40)

0.279